Unmet Needs, Future Directions, and Clinical Pearls in mCRPC
Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.
The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer
Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.
Factors for Consideration When Selecting Treatments for Patients with mCRPC
Stephen J. Freedland, MD, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case and outlines which factors, including clinical data, inform his treatment decision-making.
Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
Dr Stephen J. Freedland reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.
Case Presentation: A 67-Year-Old-Man with Metastatic Prostate Cancer
Stephen J. Freedland, MD, presents the case of a 67-year-old man with metastatic prostate cancer and give his initial impression.
Exciting Emerging Data in Prostate Cancer
Stephen J. Freedland, MD, highlights emerging data to look out for that might address unmet needs in prostate cancer testing and treatment.
Clinical Implications of Using Genomic Testing Results in Prostate Cancer Risk-Stratification and Treatment Selection
Dr Freedland discusses the clinical implications of using genomic test results for management of patients with prostate cancer.
Clinical Study Data in Prostate Cancer Genomic Testing
A key opinion leader provides an overview of study data investigating the clinical validity and clinical utility of the currently available genomic testing options in prostate cancer.
Available Genomic Tests for Clinically Localized Prostate Cancer
A review of the currently available genomic testing options for patients with clinically localized prostate cancer and the NCCN and AUA/ASTRO recommendations based on risk group.
Addressing Clinical Challenges of Prostate Cancer Management with the Use of Genomic Testing
Stephen J. Freedland, MD, details which patient populations he orders genomic testing for, and how the tests can address clinical challenges in prostate cancer treatment.
The Potential for Overtreatment or Undertreatment of Prostate Cancer
An expert urologist explains the potential for overtreatment of low-risk prostate cancer and undertreatment of high-risk prostate cancer and the potential consequences for patients.
Clinical Challenges Surrounding Treatment Decision-Making in Clinically Localized Prostate Cancer
A focused discussion on the challenges that urologists commonly face during the treatment decision-making process, and which factors typically inform treatment selection for clinically localized prostate cancer.
Treatment Options for High-Risk, Clinically Localized Prostate Cancer
Dr Stephen Freedland outlines the currently available, NCCN-recommended treatment options for patients with high-risk, clinically localized prostate cancer, and the clinical challenges he faces during the treatment decision-making process.
Staging, Grading, and Risk Stratification of Prostate Cancer
Stephen J. Freedland, MD, describes the process of diagnosing, grading, staging, and stratifying risk for patients with prostate cancer and the typical tests he uses in his clinical practice.
2 Clarke Drive Cranbury, NJ 08512